Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) EPS (Basic) (2022 - 2026)

Atara Biotherapeutics filings provide 5 years of EPS (Basic) readings, the most recent being -$0.29 for Q1 2026.

  • On a quarterly basis, EPS (Basic) fell 108.22% to -$0.29 in Q1 2026 year-over-year; TTM through Mar 2026 was -$0.76, a 70.43% increase, with the full-year FY2025 number at $2.61, up 122.87% from a year prior.
  • EPS (Basic) hit -$0.29 in Q1 2026 for Atara Biotherapeutics, up from -$0.35 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $3.53 in Q1 2025 to a low of -$16.91 in Q2 2023.
  • Median EPS (Basic) over the past 5 years was -$0.73 (2022), compared with a mean of -$3.48.
  • Biggest five-year swings in EPS (Basic): tumbled 9494.44% in 2023 and later skyrocketed 162.48% in 2025.
  • Atara Biotherapeutics' EPS (Basic) stood at -$0.73 in 2022, then crashed by 1806.85% to -$13.92 in 2023, then soared by 99.5% to -$0.07 in 2024, then crashed by 400.0% to -$0.35 in 2025, then rose by 17.14% to -$0.29 in 2026.
  • The last three reported values for EPS (Basic) were -$0.29 (Q1 2026), -$0.35 (Q4 2025), and -$0.32 (Q3 2025) per Business Quant data.